Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (796)	11/29/2000 9:28:05 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1139

DJ Newswires picks up coverage of IC 351 or Cialis.... +++++++++++ November 29, 2000 Lilly, Icos Say Drug Cialis Shows Promise as Pill to Treat Impotence Dow Jones Newswires WASHINGTON -- Following the trail of little blue Viagra pills that single-handedly ignited the impotence market, Eli Lilly & Co. and partner Icos Corp. announced positive results of their own treatment for erectile dysfunction. The pill, Cialis, helped three times as many impotent men than a sugar pill did in an intermediate study of 212 men. The research, which found that 88% of men taking Cialis had improved erections compared with 28% of men who were given a inactive sugar pill, will be presented at the Ninth World Meeting on Impotence Research in Perth, Australia. Now the drug is being tested in larger studies and the companies plan to submit an application to the Food and Drug Administration in the second half of 2001 to have the drug approved for sale in the U.S. Cialis, like Pfizer Inc.'s Viagra, works to relax the smooth muscles in the penis to allow blood to flow in so that men can achieve and maintain an erection. Alex Zisson, pharmaceutical analyst at Chase H&Q, said there should be room for Cialis in the market dominated by Viagra, which grabbed $332 million in sales for the third quarter. "Cialis looks very, very similar to Viagra," Mr. Zisson said. "There is no market, especially a billion-dollar market, that is fully satisfied by one drug. The second and third drugs usually expand the market." In the studies, Cialis users haven't complained about experiencing bluish tints in their vision, a side effect reported by Viagra users. This could encourage some users to favor Cialis, if indeed it produces fewer side effects, the analyst said. Although there hasn't been a head-to-head study comparing Cialis to Viagra, Dr. Albert Yu, senior director of clinical research at Icos, said Cialis is more potent and more selective than Viagra.